Akebia Therapeutics, Inc.
AKBA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -17.7% | -33.5% | 38.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.6% | 61.9% | 92.3% | 61.5% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -8.6% | -4.2% | 1% | -89.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -43.3% | -26.7% | -32.2% | -133.3% |
| EPS Diluted | -0.33 | -0.28 | -0.58 | -1.48 |
| % Growth | -17.9% | 51.7% | 60.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |